Disc Medicine, Inc. (IRON): Cash & Equivalents
$91.14M
As of 2025-12-31
$98.68M
As of 2026-06-30
-22.3%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $91.14M | -52.6% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $192.43M | -46.6% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $360.38M | +85.2% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $194.61M | +121.1% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $88.04M | n/c | 2023-03-31, Balance as of period end |
| 2020-12-31 | $4.50M | n/a | 2022-03-10, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | 2025-12-31 | $91.14M | -52.6% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $737.06M | +88.0% |
| MannKind Corp (MNKD) | 2025-12-31 | $74.88M | +61.6% |
| uniQure N.V. (QURE) | 2025-12-31 | $80.24M | -49.5% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $144.84M | +256.3% |
| Belite Bio, Inc (BLTE) | 2025-12-31 | $352.93M | n/m |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $120.50M | -5.6% |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $85.72M | -4.1% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $296.68M | +33.3% |
Compare IRON, OCUL, MNKD, QURE side by side · Screen every company in Pharmaceutical Preparations ↗